This review highlights the high incidence and risk factors for deep vein thrombosis in hospitalized medical and surgical patients, introducing rivaroxaban as a new oral Factor Xa inhibitor.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Steve Chaplin (2008) conducted a review in Deep vein thrombosis (DVT). Rivaroxaban was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: